(Q36377276)

13 August 2017

1 reference

title

Hepatitis C and steatosis: a reappraisal (English)

1 reference

13 August 2017

0 references

1 reference

Lonardo A

1

1 reference

13 August 2017

Loria P

2

1 reference

13 August 2017

Adinolfi LE

3

1 reference

13 August 2017

Carulli N

4

1 reference

13 August 2017

Ruggiero G

5

1 reference

13 August 2017

1 February 2006

1 reference

Journal of Viral Hepatitis

13 August 2017

1 reference

13 August 2017

13

1 reference

13 August 2017

73-80

1 reference

13 August 2017

2

1 reference

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

13 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Weighty issues in hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Obesity and its nurturing effect on hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Hepatitis C virus and liver steatosis: when fat is not beautiful

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Epidemiology of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Host genetic factors influence disease progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Course and outcome of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Natural history of chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Steatosis and intrahepatic hepatitis C virus in chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Steatosis affects chronic hepatitis C progression in a genotype specific way

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

The impact of diabetes and obesity on liver histology in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Hepatic steatosis in patients with chronic hepatitis C virus infection. Another risk factor for hepatocellular carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00669.X

10.1111/J.1365-2893.2005.00669.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference